Patents by Inventor James Harrison Aylward

James Harrison Aylward has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 10143638
    Abstract: The present invention relates generally to the cosmetic treatment of aged skin. More specifically, the invention relates to the use of ingenol compounds, particularly ingenol angelates, in treating photo-aged and/or chronologically-aged skin.
    Type: Grant
    Filed: February 12, 2010
    Date of Patent: December 4, 2018
    Assignee: LEO Laboratories Limited
    Inventors: Steven Martin Ogbourne, David Thomas, Ryan Moseley, James Harrison Aylward
  • Patent number: 9895334
    Abstract: The present invention relates generally to the treatment of cutaneous lesions containing cells infected by a virus, as well as compositions for the treatment of such lesions. More specifically, the invention relates to the use of ingenol compounds, particularly ingenol angelates, in treating lesions caused by infection with a papilloma virus, such as a mammalian papilloma virus, in particular a Human Papilloma Virus.
    Type: Grant
    Filed: April 30, 2008
    Date of Patent: February 20, 2018
    Assignee: LEO Laboratories Limited
    Inventors: Steven Martin Ogbourne, Andreas Suhrbier, James Harrison Aylward
  • Patent number: 9314458
    Abstract: The present invention relates generally to chemical agents useful in the treatment and prophylaxis of inflammatory conditions or in the amelioration of symptoms resulting from or facilitated by an inflammatory condition in a mammalian animal including human and primate, non-mammalian animal and avian species. More particularly, the present invention provides a chemical agent of the macrocyclic diterpene family obtaining from a member of the Euphorbiaceae family of plants or botanical or horticultural relatives thereof or derivatives or chemical analogs or chemically synthetic forms of the agents for use in the treatment or prophylaxis of an inflammatory condition or in the amelioration of symptoms resulting from or facilitated by an inflammatory condition in a mammal, animal or avian species.
    Type: Grant
    Filed: February 24, 2011
    Date of Patent: April 19, 2016
    Assignee: LEO Laboratories Limited
    Inventors: James Harrison Aylward, Peter Gordon Parsons, Andreas Suhrbier, Kathleen Anne Turner
  • Publication number: 20120041064
    Abstract: The present invention relates generally to the cosmetic treatment of aged skin. More specifically, the invention relates to the use of ingenol compounds, particularly ingenol angelates, in treating photo-aged and/or chronologically-aged skin.
    Type: Application
    Filed: February 12, 2010
    Publication date: February 16, 2012
    Applicant: PEPLIN RESEARCH PTY LTD
    Inventors: Steven Martin Ogbourne, David Thomas, Ryan Moseley, James Harrison Aylward
  • Publication number: 20110213002
    Abstract: The present invention relates generally to chemical agents useful in the treatment and prophylaxis of inflammatory conditions or in the amelioration of symptoms resulting from or facilitated by an inflammatory condition in a mammalian animal including human and primate, non-mammalian animal and avian species. More particularly, the present invention provides a chemical agent of the macrocyclic diterpene family obtaining from a member of the Euphorbiaceae family of plants or botanical or horticultural relatives thereof or derivatives or chemical analogues or chemically synthetic forms of the agents for use in the treatment or prophylaxis of an inflammatory condition or in the amelioration of symptoms resulting from or facilitated by an inflammatory condition in a mammal, animal or avian species.
    Type: Application
    Filed: February 24, 2011
    Publication date: September 1, 2011
    Applicant: Peplin Research Pty Ltd.
    Inventors: James Harrison Aylward, Peter Gordon Parsons, Andreas Suhrbier, Kathleen Anne Turner
  • Patent number: 7838555
    Abstract: The present invention relates to the treatment of acne vulgaris in a subject by administering to the subject an ingenane of the formula wherein R24-R26 are herein defined.
    Type: Grant
    Filed: December 9, 2002
    Date of Patent: November 23, 2010
    Assignee: Peplin Research Pty Ltd
    Inventors: James Harrison Aylward, Peter Gordon Parsons, Andreas Suhrbier, Kathleen Anne Turner
  • Publication number: 20100204318
    Abstract: The present invention relates generally to the treatment of cutaneous lesions containing cells infected by a virus, as well as compositions for the treatment of such lesions. More specifically, the invention relates to the use of ingenol compounds, particularly ingenol angelates, in treating lesions caused by infection with a papilloma virus, such as a mammalian papilloma virus, in particular a Human Papilloma Virus.
    Type: Application
    Filed: April 30, 2008
    Publication date: August 12, 2010
    Applicant: PEPLIN RESEARCH PTY LTD
    Inventors: Steven Martin Ogbourne, Andreas Suhrbier, James Harrison Aylward
  • Publication number: 20100048698
    Abstract: The present invention relates generally to chemical agents useful in the treatment and prophylaxis of inflammatory conditions or in the amelioration of symptoms resulting from or facilitated by an inflammatory condition in a mammalian animal including human and primate, non-mammalian animal and avian species. More particularly, the present invention provides a chemical agent of the macrocyclic diterpene family obtaining from a member of the Euphorbiaceae family of plants or botanical or horticultural relatives thereof or derivatives or chemical analogues or chemically synthetic forms of the agents for use in the treatment or prophylaxis of an inflammatory condition or in the amelioration of symptoms resulting from or facilitated by an inflammatory condition in a mammal, animal or avian species.
    Type: Application
    Filed: August 18, 2009
    Publication date: February 25, 2010
    Applicant: PEPLIN RESEARCH PTY LTD.
    Inventors: James Harrison Aylward, Peter Gordon Parsons, Andreas Suhrbier, Kathleen Anne Turner
  • Patent number: 7449492
    Abstract: The present invention relates generally to chemical agents useful in the treatment and prophylaxis of infection by pathogenic or potentially pathogenic entities, or entities capable of opportunistic infection in mammals, including humans and primates, non-mammalian animals and avian species. More particularly, the present invention provides a chemical agent of the macrocyclic diterpene family obtainable from a member of the Euphorbiaceae family of plants or botanical or horticultural relatives thereof or derivatives or chemical analogues or chemically synthetic forms of the agents for use in the treatment or prophylaxis of infection by pathogenic entities in mammalian, animal and avian subjects.
    Type: Grant
    Filed: December 9, 2002
    Date of Patent: November 11, 2008
    Assignee: Peplin Research Pty, Ltd.
    Inventors: James Harrison Aylward, Peter Gordon Parsons, Andreas Suhrbier, Kathleen Anne Turner
  • Patent number: 7410656
    Abstract: This invention relates to a compound or group of compounds present in an active principle derived from plants of species Euphorbia peplus, Euphorbia hirta and Euphorbia drummondii, and to pharmaceutical compositions comprising these compounds. Extracts from these plants have been found to show selective cytotoxicity against several different cancer cell lines. The compounds are useful in effective treatment of cancers, particularly malignant melanomas and squamous cell carcinomas (SCCs). In a preferred embodiment of the invention, the compound is selected from the group consisting of jatrophanes, pepluanes, paralianes and ingenanes, and pharmaceutically-acceptable salts or esters thereof, and more particularly jatrophanes of Conformation II.
    Type: Grant
    Filed: July 22, 2004
    Date of Patent: August 12, 2008
    Assignee: Peplin Research Pty. Ltd.
    Inventor: James Harrison Aylward
  • Patent number: 7378445
    Abstract: A chemical agent of the diterpene family obtained from a member of the Euphorbiaceae family of plants for use in the treatment of prophylaxis of prostate cancer or a related cancer or condition.
    Type: Grant
    Filed: January 3, 2006
    Date of Patent: May 27, 2008
    Assignee: Peplin Research Pty. Ltd.
    Inventors: James Harrison Aylward, Peter Gordon Parsons
  • Patent number: 6844013
    Abstract: This invention relates to a compound or group of compounds present in an active principle derived from plants of species Euphorbia peplus, Euphorbia hirta and Euphorbia drummondii, and to pharmaceutical compositions comprising these compounds. Extracts from these plants have been found to show selective cytotoxicity against several different cancer cell lines. The compounds are useful in effective treatment of cancers, particularly malignant melanomas and squamous cell carcinomas (SCCs). In a preferred embodiment of the invention, the compound is selected from the group consisting of jatrophanes, pepluanes, paralianes and ingenanes, and pharmaceutically-acceptable salts or esters thereof, and more particularly jatrophanes of Conformation II.
    Type: Grant
    Filed: June 21, 2001
    Date of Patent: January 18, 2005
    Assignee: Peplin Research Pty Ltd
    Inventor: James Harrison Aylward
  • Patent number: 6787161
    Abstract: This invention relates to a compound or group of compounds present in an active principle derived from plants of species Euphorbia peplus, Euphorbia hirta and Euphorbia drummondii, and to pharmaceutical compositions comprising these compounds. Extracts from these plants have been found to show selective cytotoxicity against several different cancer cell lines. The compounds are useful in effective treatment of cancers, particularly malignant melanomas and squamous cell carcinomas (SCCs). In a preferred embodiment of the invention, the compound is selected from the group consisting of jatrophanes, pepluanes, paralianes and ingenanes, and pharmaceutically-acceptable salts or esters thereof, and more particularly jatrophanes of Conformation II.
    Type: Grant
    Filed: June 21, 2001
    Date of Patent: September 7, 2004
    Assignee: Peplin Biotech Pty. Ltd.
    Inventor: James Harrison Aylward
  • Publication number: 20030195168
    Abstract: The present invention relates generally to chemical agents useful in the treatment and prophylaxis of protein kinase C (PKC) related conditions in mammals, including humans and primates, non-mammalian animals and avian species. More particularly, the present invention provides a chemical agent of the macrocyclic diterpene family obtainable from a member of the Euphorbiaceae family of plants or botanical or horticultural relatives thereof or derivatives or chermical analogues or chemically synthetic forms of the agents for use in the treatment or prophylaxis of PKC-related conditions in mammalian, animal and avian subjects. The subject chemical agents are also useful for modulating expression of genetic sequences including promotion and other regulatory sequences.
    Type: Application
    Filed: December 9, 2002
    Publication date: October 16, 2003
    Inventors: James Harrison Aylward, Peter Gordon Parsons, Andreas Suhrbier, Kathleen Anne Turner
  • Publication number: 20030171334
    Abstract: A chemical agent of the diterpene family obtained from a member of the Euphorbiaceae family of plants for use in the treatment of prophylaxis of prostate cancer or a related cancer or condition.
    Type: Application
    Filed: February 24, 2003
    Publication date: September 11, 2003
    Inventors: James Harrison Aylward, Peter Gordon Parsons
  • Publication number: 20030171337
    Abstract: The present invention relates generally to chemical agents useful in the treatment and prophylaxis of inflammatory conditions or in the amelioration of symptoms resulting from or facilitated by an inflammatory condition in a mammalian animal including human and primate, non-mammalian animal and avian species. More particularly, the present invention provides a chemical agent of the macrocyclic diterpene family obtaining from a member of the Euphorbiaceae family of plants or botanical or horticultural relatives thereof or derivatives or chemical analogues or chemically synthetic forms of the agents for use in the treatment or prophylaxis of an inflammatory condition or in the amelioration of symptoms resulting from or facilitated by an inflammatory condition in a mammal, animal or avian species.
    Type: Application
    Filed: December 9, 2002
    Publication date: September 11, 2003
    Inventors: James Harrison Aylward, Peter Gordon Parsons, Andreas Suhrbier, Kathleen Anne Turner
  • Publication number: 20030166613
    Abstract: The present invention relates generally to chemical agents useful in the treatment and prophylaxis of infection by pathogenic or potentially pathogenic entities, or entities capable of opportunistic infection in mammals, including humans and primates, non-mammalian animals and avian species. More particularly, the present invention provides a chemical agent of the macrocyclic diterpene family obtainable from a member of the Euphorbiaceae family of plants or botanical or horticultural relatives thereof or derivatives or chemical analogues or chemically synthetic forms of the agents for use in the treatment or prophylaxis of infection by pathogenic entities in mammalian, animal and avian subjects.
    Type: Application
    Filed: December 9, 2002
    Publication date: September 4, 2003
    Inventors: James Harrison Aylward, Peter Gordon Parsons, Andreas Suhrbier, Kathleen Anne Turner
  • Patent number: 6432452
    Abstract: This invention relates to a compound or group of compounds present in an active principle derived from plants of the species Euphorbia peplus, Euphorbia hirta and Euphorbia drummondii, and to pharmaceutical compositions comprising these compounds. Extracts from these plants have been found to show selective cytotoxicity against several different cancer cell lines. The compounds are useful in effective treatment of cancers, particularly malignant melanomas and squamous cell carcinomas (SCCs). In a preferred embodiment of the invention, the compound is selected from the group consisting of jatrophanes, pepluanes, paralianes and ingenanes, and pharmaceutically-acceptable salts or esters thereof, and more particularly jatrophanes of Conformation II.
    Type: Grant
    Filed: July 28, 2000
    Date of Patent: August 13, 2002
    Assignee: Peplin Biotech Pty. Ltd.
    Inventor: James Harrison Aylward
  • Publication number: 20020076457
    Abstract: This invention relates to a compound or group of compounds present in an active principle derived from plants of species Euphorbia peplus, Euphorbia hirta and Euphorbia drummondii, and to pharmaceutical compositions comprising these compounds. Extracts from these plants have been found to show selective cytotoxicity against several different cancer cell lines. The compounds are useful in effective treatment of cancers, particularly malignant melanomas and squamous cell carcinomas (SCCs). In a preferred embodiment of the invention, the compound is selected from the group consisting of jatrophanes, pepluanes, paralianes and ingenanes, and pharmaceutically-acceptable salts or esters thereof, and more particularly jatrophanes of Conformation II.
    Type: Application
    Filed: June 21, 2001
    Publication date: June 20, 2002
    Inventor: James Harrison Aylward
  • Publication number: 20010051644
    Abstract: This invention relates to a compound or group of compounds present in an active principle derived from plants of species Euphorbia peplus, Euphorbia hirta and Euphorbia drummondii, and to pharmaceutical compositions comprising these compounds. Extracts from these plants have been found to show selective cytotoxicity against several different cancer cell lines. The compounds are useful in effective treatment of cancers, particularly malignant melanomas and squamous cell carcinomas (SCCs). In a preferred embodiment of the invention, the compound is selected from the group consisting of jatrophanes, pepluanes, paralianes and ingenanes, and pharmaceutically-acceptable salts or esters thereof, and more particularly jatrophanes of Conformation II.
    Type: Application
    Filed: June 21, 2001
    Publication date: December 13, 2001
    Inventor: James Harrison Aylward